Empirical Ventures

www.empiricalventures.vc

VCMatch tracks Empirical Ventures as an investor focused on Biotech, Medtech, and Digital Health companies, Pre-Seed and Seed rounds, United Kingdom and Europe markets, and $1m to $4m check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$1m to $4m

Stages

Pre-Seed, Seed

Focus Areas

Biotech, Medtech, Digital Health

Geography

United Kingdom and Europe

Investment Thesis

Empirical Ventures is a specialist VC and venture builder that backs Europe’s best early-stage deep-tech and science-led startups. They combine deep scientific expertise (PhD founders and team), entrepreneurial and operator experience, and capital to convert fundamental research into scalable, IP-rich companies that both address major global challenges (climate, resource scarcity, healthcare) and generate financial returns. Their process emphasises rigorous, evidence-first evaluation and active company building to de-risk pre-seed/seed investments and increase probability of Series A outcomes.

Is Empirical Ventures right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Empirical Ventures is most relevant for founders raising Pre-Seed and Seed rounds in Biotech, Medtech, Digital Health, and AI/ML, especially across United Kingdom and Europe, with public check-size signals around $1m to $4m.

Focus statement

They target early-stage, IP-rich deep science technologies emerging from fundamental research across Life Sciences, Advanced Materials, TechBio, Photonics & Quantum Hardware, Robotics & Automation, AgChem/Tech and related DeepTech — prioritising solutions to real-world problems with competitive defensibility and clear scale/exit potential.

Value Add

Team of scientist-investors and operators: co-founders and staff hold PhDs across physics, chemistry, advanced materials, tissue engineering and nanomaterials, giving domain technical due diligence in-house.
Venture builder model: explicitly describes itself as a 'specialist VC and venture builder' that leads pre-seed and seed rounds and takes board/operational roles to scale companies.
Best-in-class, evidence-driven due diligence: proprietary internal scoring system, Investment Memo Questionnaire, data-room driven due diligence and an Investment Committee that reviews and sanctions reports ('Show us the evidence, so we can build conviction.').
University spinout focus and strong academic pipeline: multiple portfolio companies are university spinouts (Imperial, Bristol, Bath, etc.) and the firm highlights work with Spin Up Science and accelerator programmes.
Sector breadth within deep science: explicit sector list (Life Sciences, Advanced Materials, TechBio, Photonics & Quantum Hardware, Robotics and Automation, AgChem/Tech and DeepTech) while remaining specialised in science-first ventures.
Syndication and co-investor relationships: operates Science Angel Syndicate, works with co-investors like Parkwalk, SFC Capital and external angel networks to syndicate rounds and de-risk follow-on investment.
Operational track record metrics called out publicly: '55 deep science angel investments', '8 companies created', involvement on boards and follow-on funding evidence in portfolio news.